GlassScriptPhysician profile
Petra Jonsson Razdan
NPI 1548438880
$7,280.17
in general payments reported to CMS, 2019-2025
35 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $153 · 2021: $584 · 2022: $722 · 2023: $1,118 · 2024: $2,968 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,275 · Consulting Fee: $2,143 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,274.59 |
| Consulting Fee | $2,142.92 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Consortium of Independent Immunology Clinics, LLC | $2,142.92 | 2024-2025 | |
| Genzyme Corporation | $1,288.84 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,231.41 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $345.94 | 2021-2025 | Takhzyro, Hyqvia, Cuvitru |
| Csl Behring | $255.45 | 2020-2025 | Hizentra |
| Grifols USA, LLC | $196.07 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Novartis Pharmaceuticals Corporation | $192.64 | 2019-2025 | |
| Abbvie INC. | $187.38 | 2021-2023 | |
| Amgen INC. | $186.09 | 2021-2025 | Tezspire |
| Glaxosmithkline, LLC. | $142.38 | 2019-2025 | Nucala |
| Pfizer INC. | $118.39 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $105.95 | 2019-2024 | Dupixent |
| Hospira, INC. | $100.56 | 2024-2025 | |
| Genentech USA, INC. | $86.35 | 2021-2023 | Xolair |
| Sanofi-Aventis U.S. LLC | $85.00 | 2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $60.90 | 2022-2024 | |
| Pharming Healthcare, INC. | $60.56 | 2019-2025 | Ruconest |
| Kaleo, INC. | $51.58 | 2021-2023 | Auvi-Q |
| Biocryst US Sales Co., LLC | $51.19 | 2021-2024 | Orladeyo |
| Shire North American Group INC | $49.25 | 2019 | |
| Blueprint Medicines Corporation | $48.61 | 2023-2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.34 | 2019-2024 | Stiolto Respimat, Spiriva Respimat |
| Aimmune Therapeutics, INC. | $33.65 | 2021-2023 | |
| Leo Pharma INC. | $32.28 | 2025 | Adbry |
| Sirtex Medical INC | $31.55 | 2024 | Sir-Spheres Microspheres |
| Bio Products Laboratory USA, INC. | $23.61 | 2023 | Gammaplex, Coagadex |
| Philips North America LLC | $21.38 | 2019 | |
| Arcutis Biotherapeutics, INC. | $16.21 | 2025 | Zoryve |
| Mylan Specialty L.P. | $14.59 | 2021 | |
| Lilly USA, LLC | $14.14 | 2025 | Ebglyss |
| Ars Pharmaceuticals Operations, INC. | $13.70 | 2025 | Neffy |
| Incyte Corporation | $13.05 | 2021 | |
| Horizon Therapeutics Plc | $12.97 | 2021 | |
| Alk-Abello, INC | $12.31 | 2022 | |
| Biocryst Pharmaceuticals, INC. | $11.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,878.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Petra Jonsson Razdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.